Abstract

Background: Peripheral artery disease (PAD) is an important predictor of adverse outcomes after coronary revascularization. Patients with PAD have been found to have higher rates of adverse outcomes and poorer survival compared with patients without PAD. However, there have been limited data for long term clinical outcomes in patients with PAD undergoing percutaneous coronary intervention (PCI)in drug eluting stent (DES) era. Method: The study population consisted of 2903 consecutive patients underwent PCI enrolled from April 2007 to Novenber 2010. 2-year cumulative major clinical outcomes of patients with PAD group (n=101 pts) were compared with patients without PAD group (n=2802 pts). Result: Compared with patients without PAD, Patients with PAD were more older, had diabetes (66.76±10.09 vs. 62.90±11.30 yrs, p=0.020 and 61.8 vs 27.6%, p=0.002). There was no significant difference in the angiographic characteris except total lesion length (50.38±47.14 vs. 41.24±39.93, p=0.005) Patients with PAD had trend toward higher rate of total mortality (13.6 vs 6.3%, p = 0.051), but There was no significant difference in cardiac death, target lesion revascularization (TLR), target vessel revascularization (TVR), major adverse cardiac events (MACE). (Table 1) ![Figure][1] Conculsion: In our study, patients with PAD was associated with total mortality up to 2 years as compared to those without PAD group. However, PAD had not affect clinical outcomes after successful PCI. [1]: pending:yes

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.